Gene Therapy and Testosterone Enhancement

April 29, 2012, 8:20 am

≫ Next: SUMMER SCHOOL IN PERL/BIOPERL & LIVE BIOINFORMATICS PROJECTS

≪ Previous: Biotech web sites

$

0

0

What would be a potential application of gene therapy for raising the body's baseline testosterone levels in men????
I was thinking whether it would be possible in the near future for gene therapy to work on the hippocampus in increasing the amount of GnRH released and thus LH and testosterone. Any thoughts?????

---

SUMMER SCHOOL IN PERL/BIOPERL & LIVE BIOINFORMATICS PROJECTS

April 30, 2012, 1:19 am

≫ Next: Career Questions:Trends in research positions

≪ Previous: Gene Therapy and Testosterone Enhancement

$

0

0

SUMMER SCHOOL IN PERL/BIOPERL & LIVE BIOINFORMATICS PROJECTS

Our research group under the leadership of Dr. Kamal Rawal (PhD, Bioinformatics) has been working on several bioinformatics projects. We have made significant contributions in the area of bioinformatics. Our research is at par with leading universities in the world. Our recent publication(s) in highly reputed journals such as Nucleic Acids Research speaks volumes about how much we value quality research. Here we mined several hundred GBs of genomic data, discovered patterns and developed software pipeline. Prior to that, we have published in several international journals majorly in the area of computational genome analysis and text mining. In most of these research studies, perl and bioperl has played a major role in method development, algorithm implementation, data extraction & analysis, parsing, automation, software development etc. Every year we receive several applications from students of reputed universities to learn perl, bioperl and do project in our lab. Considering this, we would like to share our learning and expertise in the area of Perl and bioperl with others through this summer school.

Features-
A) Skill based training on perl and bioperl (Module 1)
B) Hands on Training on live projects pertaining to genome analysis, automation, large scale data integration, working on giga bytes of data using perl scripts, using super computing facilities, working knowledge of linux for perl, bioperl, design and implementation of algorithms, text mining, network biology etc. (Module 2)
C) Working on live project under expert bioinformaticians. (Module 3)
This Summer School is aimed at early-stage researchers (B. Tech, BSC, MSC, PhD students, postdocs and clinician-scientists) with little or no experience in computational biology, perl bioperl etc, and will deliver a broad understanding of bioinformatics research tools currently available. This school will also expose students to fine nuances of perl & bio perl programming and its application in projects such as genome annotation, text mining and systems biology.

When: Jun 12, 2012 to July 7, 2012
Where: Jaypee Institute of Information Technology, Noida , India

Major Lectures
10 AM till 12 noon every week days. Rest of the time will be for practical trainings

The course will provide practical, hands-on training in bioinformatics as well as in perl/bioperl in the context of the latest biomedical and biological research, as well as serving as a forum for the interchange of ideas and expertise between various participants.

To optimize practical training and interaction between participants and trainers, places on the Summer School are limited to 40.
The programme will provide:
• A broad introduction to perl, bioperl and bioinformatics data resources (through lecture- and practical-based sessions)
• An understanding of when, why and how to use public data resources for molecular biology
• Practical experience of using perl and bioperl , using a range of widely applicable case studies

This is a self supporting summer school with 5 seats offered as free to meritorious students.

Deserving and meritorious students will be provided scholarship to attend this program. They must write an essay -:

"Given my background and interests how this course will help me to enhance my skills"
OR
" Why I should be given chance to attend this summer school ?"


Proceeds- The proceeds or revenue generated shall be donated to setting up of High performance computing facility for bioinformatics research at JIIT Noida under the Department of Biotechnology.

Cost for students/academic-
A) Module 1– 5000 Rs per applicant
B) Module 2- 4000 Rs per applicant
C) Module 3- 3000 Rs per applicant


Cost for Corporate-

A) Module 1 – 15000 Rs per applicant
B) Module 2- 14000 Rs per applicant
C) Module 3- 10000 Rs per applicant


SPECIAL DISCOUNT AND SLOTS FOR JAYPEE STUDENTS!!! All three modules at just Rs.5000/- !!!

To help students pay less or get discounts or even make it free, we are also attempting to get sponsorship from corporate entities as well as funding from government bodies to fund this entire school. So apply, if you are deserving & passionate we will try to admit you. So send applications to email listed below.

The enrolment may be done independently for each module.


Outstation participants shall be assisted in finding accommodation. The hostel facility might be extended to candidates depending upon necessary approvals from university administration Excellent food at nominal cost (Rs 30 per meal) is available at JIIT cafeteria.

Please note: In case number of applications exceed the available slots then seats will be awarded on merit and applicants must submit a completed application form as part of the registration process.

Last date for Applications: 15th May,2012

There will be possibility of guest lectures of experts from various universities under this program.

Key Trainer

Dr. Kamal Rawal (PhD, Bioinformatics) JNU
He has been working on perl and bioperl for the past 10 years. You may read his profile at:

https://sites.google.com/site/obesityaco...ap/contact


Email your CV to:

jiit-bioinformatics@googlegroups.com
kamal.rawal@gmail.com

Career Questions:Trends in research positions

May 3, 2012, 9:03 am

≫ Next: enGENEious: a synthetic biology, biotechnology conference at the University of Oxford

≪ Previous: SUMMER SCHOOL IN PERL/BIOPERL & LIVE BIOINFORMATICS PROJECTS

$

0

0

I am a Masters graduate in Bioengineering with over an year of work experience with a top Biomedical device company in product development. However, I have decided to make a switch to academia to spend more time on core research projects. I have an offer right now from a reputed academic institution with a salary offer in the range of $40,000-$45,000/annum. Unfortunately I am not familiar with the academic environment and I need some feedback on the current trends and whether this is a good offer for my level of experience taking into consideration the current economic conditions. To give you more information, I am highly interested in the research project and I am provided with a competitive benefits package. What are some of the options for future career growth for research specialists 1) if they stick to academic research 2) if they wish to diverge to an industrial career? Thank you for your time and attention. Could you give me some pointers on what aspects to consider when considering an academic job offer?

enGENEious: a synthetic biology, biotechnology conference at the University of Oxford

May 3, 2012, 3:04 pm

≫ Next: enGENEious: a synthetic biology, biotechnology conference at the University of Oxford

≪ Previous: Career Questions:Trends in research positions

$

0

0

enGENEious is a two-day conference on cutting edge research in synthetic biology and biotechnology. This international event has been organised by students and post-docs of the University of Oxford to allow future researchers to meet pioneers who have made outstanding contributions in this field.

http://engeneious.chem.ox.ac.uk/

Abstract deadline: 30th May 2012; Registration deadline: 30th May 2012

Also see Flash Talks.

enGENEious: a synthetic biology, biotechnology conference at the University of Oxford

May 3, 2012, 3:06 pm

≫ Next: enGENEious: a synthetic biology, biotechnology conference at the University of Oxford

≪ Previous: enGENEious: a synthetic biology, biotechnology conference at the University of Oxford

$

0

0

enGENEious is a two-day conference on cutting edge research in synthetic biology and biotechnology. This international event has been organised by students and post-docs of the University of Oxford to allow future researchers to meet pioneers who have made outstanding contributions in this field.

http://engeneious.chem.ox.ac.uk/

Abstract deadline: 30th May 2012; Registration deadline: 30th May 2012

Register for a FLASH TALK to win an iPAD!

enGENEious: a synthetic biology, biotechnology conference at the University of Oxford

May 3, 2012, 3:07 pm

≫ Next: Pharmacovigilance Training in Oracle Argus Safety Database

≪ Previous: enGENEious: a synthetic biology, biotechnology conference at the University of Oxford

$

0

0

enGENEious is a two-day conference on cutting edge research in synthetic biology and biotechnology. This international event has been organised by students and post-docs of the University of Oxford to allow future researchers to meet pioneers who have made outstanding contributions in this field.

http://engeneious.chem.ox.ac.uk/

Abstract deadline: 30th May 2012; Registration deadline: 30th May 2012

Register for a FLASH TALK to win an iPAD!

Pharmacovigilance Training in Oracle Argus Safety Database

May 9, 2012, 7:54 am

≫ Next: Pharmacovigilance Training in Oracle Argus Safety Database

≪ Previous: enGENEious: a synthetic biology, biotechnology conference at the University of Oxford

$

0

0

Pharmacovigilance Training in Oracle Argus Safety Database with Internship

Organization at a Glance:

Gratisol Labs is a leading Clinical Research organization providing full range of Clinical Research, Clinical Data Management, CDISC SDTM, Pharmacovigilance & SAS training services to Healthcare Organizations globally.

The classes will be conducted at ‘GRATISOL LABS’, Road No.10, Banjara Hills, Hyderabad.

The focus of the lectures will be mainly on the following topics:

• History and over view of pharmacovigilance
• Introduction and responsibilities: USFDA, EMA and CDSCO
• Pharmacovigilance in India
• Clinical Development process
• Different phases of clinical Trials
• Adverse events and its types
• Drug Safety in clinical trials and post marketed drugs
• Different sources of Adverse events reporting
• Different types of AE reporting Forms
• Expedited reporting and its timelines
• Different departments working on Pharmacovigilance
• Roles and responsibilities of case receipt unit
• Roles and responsibilities of Triage unit
• Four factors for the reportable case
• Seriousness criteria of adverse event
• Expectedness or Listedness of adverse event
• Causality assessment of the adverse event
• Introduction to safety databases and different types
• Importance and procedure of duplicate check
• Case bookin or initiation
• Introduction to MedDRA and WHODD
• Narrative writing
• Case quality check, Medical review and its submission.
• The Qualified Person for Pharmacovigilance (QPPV) in the European Economic Area
• PSUR and its submission timelines
Practical Training will be also provided on Safety Database on the following topics:
• Data Entry
• Case Processing
• MedDRA & WHODD coding
• SAE narrative writing.

Mode of training- Instructor Led Class room/ Online Training

Note: Industry Experts from Novartis, Parexel, TechMahindra, Infosys, HCL, MakroCare, Aurobindo Pharma, Natco Pharma, Dr Reddys will deliver the classes.

Our candidates employed in Mahindra Satyam, GSK, Quanticate, ICMR, Global Hospitals, Apollo Hospitals, NIMS, Quintiles, Novartis, Glenmark Pharmaceuticals Ltd, Parexel International (India) Pvt Ltd, AstraZeneca-UK and many more…

To reserve the seat immediately, send a DD of Rs.500/- in favour of Gratisol Labs payable at Hyderabad along with your resume by courier or registered post. You can also reserve the seat by doing cash payment at Gratisol Labs Premises.

Tenure: 2 month

Eligibility
Applicants are recommended to have one of the following life Science degrees: Bachelor's, Master’s, or PhD, MBBS/ MD/B.D.S /M.D.S/ B.A.M.S / B.H.M.S /B.P.T/ B.Tech (Biotechnology / Pharmaceutical Science) / B. Pharm /M.Pharm /BVSC / B.Sc. (Nursing) / B.Sc./M.Sc, M.Pharmacy, M.Sc /MA (Statistics) and all professionals working with Pharmaceutical companies, CROs and Hospitals.

Certification
Certificate will be provided for this course on successful completion of Assignments & Projects. Certificate would be awarded at the end of the program by Gratisol Labs.

For more information, please contact Gratisol Labs at training@gratisol.com

For More Details: Please Contact

Kunal Singh
Training Coordinator

Gratisol Labs
Plot No: 70, 3rd Floor,
Road No-10, Banjara Hills,
Landmark: Near Star Hospitals
Hyderabad AP – 500034
Contact No: 040-65741017,64615852, 8885198390, 9705790302
E: mail: training@gratisol.com
Website: http://www.gratisol.com

Pharmacovigilance Training in Oracle Argus Safety Database

May 9, 2012, 7:57 am

≫ Next: Clinical Data Management Training in Oracle Clinical with Internship

≪ Previous: Pharmacovigilance Training in Oracle Argus Safety Database

$

0

0

Pharmacovigilance Training in Oracle Argus Safety Database with Internship

Organization at a Glance:
Gratisol Labs is a leading Clinical Research organization providing full range of Clinical Research, Clinical Data Management, CDISC SDTM, Pharmacovigilance & SAS training services to Healthcare Organizations globally.

The classes will be conducted at ‘GRATISOL LABS’, Road No.10, Banjara Hills, Hyderabad.

The focus of the lectures will be mainly on the following topics:
• History and over view of pharmacovigilance
• Introduction and responsibilities: USFDA, EMA and CDSCO
• Pharmacovigilance in India
• Clinical Development process
• Different phases of clinical Trials
• Adverse events and its types
• Drug Safety in clinical trials and post marketed drugs
• Different sources of Adverse events reporting
• Different types of AE reporting Forms
• Expedited reporting and its timelines
• Different departments working on Pharmacovigilance
• Roles and responsibilities of case receipt unit
• Roles and responsibilities of Triage unit
• Four factors for the reportable case
• Seriousness criteria of adverse event
• Expectedness or Listedness of adverse event
• Causality assessment of the adverse event
• Introduction to safety databases and different types
• Importance and procedure of duplicate check
• Case bookin or initiation
• Introduction to MedDRA and WHODD
• Narrative writing
• Case quality check, Medical review and its submission.
• The Qualified Person for Pharmacovigilance (QPPV) in the European Economic Area
• PSUR and its submission timelines

Practical Training will be also provided on Safety Database on the following topics:

• Data Entry
• Case Processing
• MedDRA & WHODD coding
• SAE narrative writing.

Mode of training- Instructor Led Class room/ Online Training
Note: Industry Experts from Novartis, Parexel, TechMahindra, Infosys, HCL, MakroCare, Aurobindo Pharma, Natco Pharma, Dr Reddys will deliver the classes.

Our candidates employed in Mahindra Satyam, GSK, Quanticate, ICMR, Global Hospitals, Apollo Hospitals, NIMS, Quintiles, Novartis, Glenmark Pharmaceuticals Ltd, Parexel International (India) Pvt Ltd, AstraZeneca-UK and many more…

To reserve the seat immediately, send a DD of Rs.500/- in favour of Gratisol Labs payable at Hyderabad along with your resume by courier or registered post. You can also reserve the seat by doing cash payment at Gratisol Labs Premises.
Tenure: 2 month
Eligibility
Applicants are recommended to have one of the following life Science degrees: Bachelor's, Master’s, or PhD, MBBS/ MD/B.D.S /M.D.S/ B.A.M.S / B.H.M.S /B.P.T/ B.Tech (Biotechnology / Pharmaceutical Science) / B. Pharm /M.Pharm /BVSC / B.Sc. (Nursing) / B.Sc./M.Sc, M.Pharmacy, M.Sc /MA (Statistics) and all professionals working with Pharmaceutical companies, CROs and Hospitals.
Certification
Certificate will be provided for this course on successful completion of Assignments & Projects. Certificate would be awarded at the end of the program by Gratisol Labs.
For more information, please contact Gratisol Labs at training@gratisol.com
For More Details: Please Contact

Kunal Singh
Training Coordinator

Gratisol Labs
Plot No: 70, 3rd Floor,
Road No-10, Banjara Hills,
Landmark: Near Star Hospitals
Hyderabad AP – 500034
Contact No: 040-65741017,64615852, 8885198390, 9705790302
E: mail: training@gratisol.com
Website: http://www.gratisol.com

---

Clinical Data Management Training in Oracle Clinical with Internship

May 9, 2012, 7:59 am

≫ Next: PG Diploma in Bioinformatics

≪ Previous: Pharmacovigilance Training in Oracle Argus Safety Database

$

0

0

Clinical Data Management Training in Oracle Clinical with Internship

Organization at a Glance:
Gratisol Labs is a leading Clinical Research organization providing full range of Clinical Research, Clinical Data Management, CDISC SDTM, Pharmacovigilance & SAS training services to Healthcare Organizations globally.
The classes will be conducted at ‘GRATISOL LABS’, Road No.10, Banjara Hills, Hyderabad.
The focus of the lectures will be mainly on the following topics:
• Introduction to Clinical Research & Clinical Data Management
• Fundamentals of Clinical Research &Roles in a CRO
• Clinical Data Management Process and Life cycle.
• ICH – GCP guidelines
• Protocol Designing
• CRF /e CRF Designing
• CRF Annotation
• SOP Preparation (Standard Operating Procedure)
• CDISC STANDARADS
• Preparation of essential documents in CDM process (Data Management Plan ,Database Structure Document, Edit Check Specification document, Study User Acceptance Test(UAT)
• Database Design
• Data Validation programming and standards
• Database testing
• Data entry
• Discrepancy Management
• DCF Management
• Electronic Data Capture and Remote Data Capture.
• Management of Medical Dictionaries(MeDDra, WhoDD)
• Query management(DCF management) Coding
• External data managing (e, g: Lab data, ECG, BMD etc.)
• Clean Patient Delivery
• Database Lock, Freeze.
• SAS data Extracts
Mode of training- Instructor Led Class room/ Online Training
Note: Industry Experts from Novartis, Parexel, TechMahindra, Infosys, HCL, MakroCare, Aurobindo Pharma, Natco Pharma, Dr Reddys will deliver the classes.

Our candidates employed in Mahindra Satyam, GSK, Quanticate, ICMR, Global Hospitals, Apollo Hospitals, NIMS, Quintiles, Novartis, Glenmark Pharmaceuticals Ltd, Parexel International (India) Pvt Ltd, AstraZeneca-UK and many more…

To reserve the seat immediately, send a DD of Rs.500/- in favour of Gratisol Labs payable at Hyderabad along with your resume by courier or registered post. You can also reserve the seat by doing cash payment at Gratisol Labs Premises.
Tenure: 2 month
Eligibility
Applicants are recommended to have one of the following life Science degrees: Bachelor's, Master’s, or PhD, MBBS/ MD/B.D.S /M.D.S/ B.A.M.S / B.H.M.S /B.P.T/ B.Tech (Biotechnology / Pharmaceutical Science) / B. Pharm /M.Pharm /BVSC / B.Sc. (Nursing) / B.Sc./M.Sc, M.Pharmacy, M.Sc /MA (Statistics) and all professionals working with Pharmaceutical companies, CROs and
Certification
Certificate will be provided for this course on successful completion of Assignments & Projects. Certificate would be awarded at the end of the program by Gratisol Labs.
For more information, please contact Gratisol Labs at training@gratisol.com
For More Details: Please Contact

Kunal Singh
Training Coordinator

Gratisol Labs
Plot No: 70, 3rd Floor,
Road No-10, Banjara Hills,
Landmark: Near Star Hospitals
Hyderabad AP – 500034
Contact No: 040-65741017,64615852, 8885198390, 9705790302
E: mail: training@gratisol.com
Website: http://www.gratisol.com

PG Diploma in Bioinformatics

May 11, 2012, 7:56 am

≫ Next: Survey: Biotech Supply Ordering Survey

≪ Previous: Clinical Data Management Training in Oracle Clinical with Internship

$

0

0

Hi all,

I completed my M.Sc Biotechnology in 2007. After that I was working in e-publication. I would like to work in life science. Could you suggest colleges in Bangalore offering PG Diploma in Bioinformatics with placements?

Survey: Biotech Supply Ordering Survey

May 15, 2012, 4:17 pm

≫ Next: East to use database to store protein sequences

≪ Previous: PG Diploma in Bioinformatics

$

0

0

Hello Biotechnology Forum members! My name is Nate and I am working on a feasibility study for a business project of mine that, if feasible, could make a beneficial contribution to the biotechnology research community. Below is a link to a survey I created so I can gather the data I need.

If you have any issues or questions, please email me at emtbn8@gmail.com. Thanks!

http://www.zoomerang.../WEB22FQVC4P889

East to use database to store protein sequences

May 16, 2012, 6:57 am

≫ Next: Warehousing: FIFO or FEFO??

≪ Previous: Survey: Biotech Supply Ordering Survey

$

0

0

Hi,
I am currently conducting an independent research on a class of proteins. With 19000 protein sequences to be stored and classified into 5 classes based on conserved domain of each class,using bioinformatic tools. What would be the best database to be used that is easy to use and will consume lesser time for such a huge number of proteins to be worked on.

I will be linking this database with a software that would identify consensus sequences.

Warehousing: FIFO or FEFO??

May 16, 2012, 12:26 pm

≫ Next: FP7 proposal "Waste-to-Energy Biotechnology" (WEB)

≪ Previous: East to use database to store protein sequences

$

0

0

I need to pose a question: What is the biotech industry standard system for raw material decrementation and why? We currently use the FIFO system, but I am thinking that FEFO may be better.

Thanks in advance for your response.

FP7 proposal "Waste-to-Energy Biotechnology" (WEB)

May 22, 2012, 8:15 am

≫ Next: my cell ideas

≪ Previous: Warehousing: FIFO or FEFO??

$

0

0

The European Profiles S.A. (Greece) together with the Institute of Microbiology and Virology (Ukraine) is developing the FP7 project “Pre-Industrial Waste-to-Energy Enabling Biotechnology based on Accelerated Fermentation of Mixed Organic Waste”. Our intention is to submit this proposal to FP7 KBBE Call expected in July 2012.
General idea of this research and demonstration project is a development of an effective technology set designed for effective conversion of mixed landfill waste biomass into energy-rich products with application of a value chain comprehensive approach. The target products include various types of biofuels. Within the same conversion chain it is expected to obtain gas (molecular hydrogen), liquid (a mixture of low-molecular alcohols) and solid (unfermented crop residues) biofuels and also valuable fermentation products such as organic acids. The core of approach to be applied is a microbial biotechnology that provides complete fermentation of various organic wastes (vegetable and food waste, plant, cellulose, paper, landfill filtrate with high soluble carbon compounds content) and will be provided by 3 research organizations experienced in waste fermentation. The efficiency of the biotechnology will be demonstrated on a laboratory-scale plant, optimized, and unrolled in the form of the plant built directly on the landfill. The project involves an interdisciplinary collaboration and includes the following organizations: research and biotechnology laboratories, equipment engineers and manufacturers, small and medium-sized enterprises, city administrations, industry representatives (energy and chemistry sector players specialized in organic synthesis), as well as experts in economic modeling, consultancy and management logistics partners.
We are looking for partners to develop a detailed successful proposal in accordance with our mutual research and business interests. In particular we are looking for companies/institutions as follows:
• EU (AC) Research institutions experienced in efficient waste fermentation / gas mixture production / separation
• EU SME experienced in microbiological plant / biofuel plant design and construction (that already took part in the framework programme
• Fuel-Cells R&D SME experienced in FP project implementation
• SME that uses biohydrogen as a final product (e.g. gases / liquids for electricity conversion, and/or uses biohydrogen in chemical reactions
We are ready to provide you with additional information if you are interested in participation in potential project and your institution/company possesses the relevant capacity/know-how. Please do not hesitate to contact us:
Dr. Vladimir Arkhangelski, Senior Consultant, European Profiles Kiev Office,
e-mail: vladimir@epukraine.com
Ms. Rania Sabanegh, Senior Consultant, European Profiles Main Office in Athens,
e-mail: rsabanegh@europeanprofiles.gr; web: http://www.europeanprofiles.gr

my cell ideas

May 23, 2012, 5:26 pm

≫ Next: Systolic blood pressure and mortality, there is a J-type curve

≪ Previous: FP7 proposal "Waste-to-Energy Biotechnology" (WEB)

$

0

0

i'm eleven years of age and i wanna be a scientist so i thought of three awsome ideas :ideas 1. use micro robots to stop virus from attacking the cell 2.put a wall of robots near endoplasmic reticulum to stop viruses if they get past the wall 3. inject robots into a soilders blood to squirt antibiotics on the cut and close the wound note:for info on 3's robots send me a message for diagram hope you like

---

Systolic blood pressure and mortality, there is a J-type curve

May 30, 2012, 12:40 am

≫ Next: Aprataxin the new found

≪ Previous: my cell ideas

$

0

0

The United States Los Angeles, researchers John Sim, Dr. in mid-2012 of the American Society of HSPB7 Hypertension meeting, one study reported that systolic blood pressure and mortality there is a J-type curve.Refractory hypertension, defined as three kinds of antihypertensive drugs can not still can not in blood pressure control (> 140/90 mm Hg), or need to use four kinds of antihypertensive drugs to maintain normal blood pressure level.Researchers believe the results to find the idea of a HSPB8 "sweet spot" for systolic blood pressure of patients with refractory hypertension. Doctors may be 150 mm Hg as its lowest point to reduce the risk of death of these patients. Not blood pressure still can not control (> 140/90 mm Hg), or need to use four kinds of antihypertensive drugs to maintain normal blood pressure level.In this longitudinal cohort study identified 58 784 patients with refractory HSPBAP1 hypertension and its three-year follow-up. The researchers compared the clinical outcome of patients with refractory hypertension and blood pressure checks records of 470,998 patients. Non-refractory hypertension in patients with average blood pressure was 132/75 mm Hg in patients with refractory hypertension, the average blood pressure was 143/74 mm Hg.The occurrence of heart failure risk in patients with refractory hypertension increased by 36%, the MI risk increased by 25%, stroke risk increased by 10%, the risk of ESRD increased by 24%. However, those patients with HSPBP1 refractory hypertension risk of death decreased by 19% (HR = 0.81, 95% CI = 0.78 to 0.84). After adjusting for age, gender, male, diabetes, pre-existing diseases - increased risk of death related to these factors, in the study period, still 19% lower mortality in patients with refractory hypertension.

The researchers found that blood pressure less than 120, 130, and 140 mm Hg in patients with HSPD1 more hypertension, the mortality rate is indeed up. When a rise in blood pressure, mortality rise was a "U" shaped or "J" shaped curve. Other outcomes such as end-stage kidney disease, stroke, myocardial infarction, associated with blood pressure between the basic linear relationship between increased blood pressure, also increased danger.Researchers believe the results to find the idea of a "sweet spot" for systolic blood pressure of patients with refractory hypertension. Doctors may be 150 mm Hg as its lowest point to reduce the risk of death of these patients.The researchers remind the reader that mortality decline should be interpreted with special attention, because these patients with refractory hypertension in the health care resource utilization has not been database records, which may reflect their treatment in different ways, which would be the death rate generator. Need for further in-depth studies are needed to verify their results, and the longitudinal cohort study of inadequacies can not be ignored. This research team is currently in-depth analysis of some of the information, to find those factors may explain the decreased risk of death and is expected in a short period of time on medication adherence results show.

Aprataxin the new found

May 30, 2012, 10:51 pm

≫ Next: Need cost info on setting up a plant biotech company in India!!

≪ Previous: Systolic blood pressure and mortality, there is a J-type curve

$

0

0

Aprataxin the new found

Normal DNA damage repair mistakes will lead to many diseases, the most representative of the neurological disorders, genetic instability increases and cancer. In various types of DNA damage, single-strand breaks are the most common frequency of tens of thousands of cells every day, if the repair missed that cause disease. Recent discovery of a hereditary neurodegenerative venereal disease ataxia with eye movement lost able to disease (AOA1,) and a class of DNA damage repair proteins Aprataxin, encoding the protein gene APTX mutations cause AOA1 the occurrence of. AOA1 is a nervous system disorder, the major symptoms of cerebellar atrophy, sensory neuropathy, leading to loss of motor coordination, eye movement can not wait for disability lesions, patients will end up in a wheelchair. The known AOA1 widely distributed in the United Kingdom and the United States, Germany, France, Australia, Italian, Japanese, Portuguese and other countries. Clearly, revealing the molecular mechanism of this process is important.
Studies confirm Aprataxin is a single strand of a DNA damage repair enzyme, can be directly catalyzed removal of single-chain fracture pollution adduct on the 5'-AMP, the default interrupt the DNA ligation reaction can be reversed. Hnt3 protein of human Aprataxin in the fission yeast ortholog, and between them have the same basic biochemistry, molecular biology and functional characteristics. The article reported Hnt3 protein and a gap of DNA, the mechanism of the reaction product AMP complex three-dimensional structure and function of the structure. Formed a unique Hnt3 and DNA identification, the role and reaction of molecular platform for the ternary complex structure, reflecting the structural basis and molecular details Hnt3 reaction before and after the reaction product combined with state, including: (1) Hnt3/Aprataxin is a special member of the widespread presence of histidine triad (HIT) superfamily of two structural units: the active site of HIT the domain, DNA binding sites ZF the domain, they are like two "molecular hand" each with DNA single-chain interactions across the 9-bp DNA double helix, covering the surface of the DNA main channel; (2) during which the complex interactions of DNA bending, disturbance near the fracture gap "pollutants" (5'-adenosine acid) structure as valgus and "fragile", the formation of the activation of the substrate structure conducive to the reaction; (3) On this basis, the HIT superfamily catalytic mechanism of removal of "pollution elements" to complete the incision blocking correction ; (4) Hnt3 only with the DNA backbone role of non-sequence dependent, it is only sensitive to the polyadenylation of DNA breaks is not subject to the constraints of the chemical specificity of universal corrector. The structure study reveals Hnt3/Aprataxin fracture correction to the gap sensor and single-chain function through a complex interaction platform; (5) The structure-based mechanistic conclusions have been reported with the current biochemical and molecular studies are basically the same, this structure reflects the mode of assembly of the physiological state of the DNA polyadenylation reveal the Hnt3/Aprataxin mutation lead to AOA1 neurological disorders major molecular mechanism and structural basis.At the same time, the study by site-directed mutagenesis and DNA interaction experiments, reveal a number of key amino acids the Hnt3 function, revealing Aprataxin a variety of pathogenic mutants in different ways (such as damage to its affinity with the substrate DNA and to adenosine enzyme activity to reduce the structural stability, etc.) interfere with DNA damage repair, which led to the structural basis of nervous system diseases.The study of neurodegenerative diseases in AOA1 mechanism provides a precise, quantitative knowledge, new principles, thus becoming an important foundation for innovative biomedical research and development of such diseases.

Need cost info on setting up a plant biotech company in India!!

June 2, 2012, 7:25 pm

≫ Next: genetic engeenering

≪ Previous: Aprataxin the new found

$

0

0

I plan to start a plant biotech company on a small scale for producing industrially and medicinally important metabolites and compounds in India.

Please give me an approx cost of setting up R&D,industrial scale up and storage (all necessary and minimally required) for producing such products.
Also give me an idea of the land requirements.

Is it possible to get these products from callus on a industrial scale cost effectively?

genetic engeenering

June 4, 2012, 10:35 am

≫ Next: Potential lethality of three types of antibiotics can damage cellular DNA

≪ Previous: Need cost info on setting up a plant biotech company in India!!

$

0

0

Which gene is responsible for biosynthesis of cinnamaldehyde in cinnamon/ please give me reply

Potential lethality of three types of antibiotics can damage cellular DNA

June 4, 2012, 8:07 pm

≫ Next: 1st Biotech Magazine "BIOTECH RINGS"

≪ Previous: genetic engeenering

$

0

0

Internationally renowned magazine "Science" in Science published the latest HSP26 research results from the Massachusetts Institute of Technology and Boston University researchers "Oxidation of the Guanine Nucleotide the Pool Underlies Cell Death by Bactericidal Antibiotics", the article, the researchers have opened a The three main types of antibiotics potentially killing mechanisms: drug generated a number of destructive molecules through a series of cellular events that caused the HSP90AA1 fatal damage to cellular DNA.Penicillin and other antibiotics pharmaceutical revolutionary change once fatal disease into in order to easily curable diseases. However, despite the antibiotics in clinical practice for more than 70 years, its exact mechanism of killing bacteria is still a mystery to be solved.The researchers said that a detailed understanding of this mechanism could help scientists HSP90AB1 improve existing drugs. In the past 40 years, only a few new antibiotics are developed, while a large number of bacterial strains but then the currently available drug tolerance.James Collins, professor of biomedical engineering at Boston University, said: "This may enhance the killing effect of our current 'arsenal' to reduce the required dose, or the bacterial strain is sensitive to existing antibiotics to.


In 2007, Collins proved that the three HSP90B1main types of antibiotics - quinolones, beta-lactams and aminoglycosides - can be to generate highly destructive hydroxyl free radicals, molecules methoxycinnamate (OMC) radicals, the destruction of bacterial cells. At that time, he and other researchers speculated that free radicals launched a comprehensive attack on all cellular components they encounter.MIT biology professor Graham Walker said: "They are almost all produced HSPA13 responses. They chase lipid, the oxidation of protein, they can oxidize DNA." However, in the new study, researchers found that this damage part is not lethal,The researchers demonstrated that the fatal injury can be caused by bacteria is the guanine damage induced by hydroxyl, guanine (G) is the four basic building blocks of DNA nucleotide one. When this damage guanine inserted into the DNA, the bacteria will endeavor to repair this damage, but eventually accelerate the death. "This is not the cause of all the killing effects of reasons, but the fact that it occupies a very important proportion of," Walker said.Initially, Walker for the study of DNA repair enzymes so that the researchers suspect that this oxidized guanine may play a role in the antibiotic-mediated cell death. In the first study phase, they found a specific DNA polymerase DinB very good use of the oxidation of guanine components to synthesize DNA.That DinB is not only oxidation of guanine during DNA replication, however, inserted into the correct base opposite cytosine © will be inserted into the opposite adenine (A).The researchers found that when too much oxidation of guanine incorporation into the new strand of DNA, the cell will not be able to successfully remove these damage, thus leading to death.